company background image
RHY

Rhythm BiosciencesASX:RHY Stock Report

Market Cap

AU$254.7m

7D

2.1%

1Y

408.3%

Updated

16 Oct, 2021

Data

Company Financials +
RHY fundamental analysis
Snowflake Score
Valuation0/6
Future Growth3/6
Past Performance0/6
Financial Health4/6
Dividends0/6

RHY Overview

Rhythm Biosciences Limited, a transformative diagnostics company, engages in developing and commercializing of medical diagnostics technology in Australia and internationally.

Price History & Performance

Summary of all time highs, changes and price drops for Rhythm Biosciences
Historical stock prices
Current Share PriceAU$1.22
52 Week HighAU$0.18
52 Week LowAU$1.68
Beta3.94
1 Month Change6.55%
3 Month Change29.10%
1 Year Change408.33%
3 Year Change741.39%
5 Year Changen/a
Change since IPO275.39%

Recent News & Updates

Jul 19
We're Hopeful That Rhythm Biosciences (ASX:RHY) Will Use Its Cash Wisely

We're Hopeful That Rhythm Biosciences (ASX:RHY) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Mar 03
Here's Why We're Not Too Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Situation

Here's Why We're Not Too Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. Indeed, Rhythm Biosciences...

Shareholder Returns

RHYAU HealthcareAU Market
7D2.1%-1.3%0.9%
1Y408.3%11.5%20.2%

Return vs Industry: RHY exceeded the Australian Healthcare industry which returned 11.5% over the past year.

Return vs Market: RHY exceeded the Australian Market which returned 20.2% over the past year.

Price Volatility

Is RHY's price volatile compared to industry and market?
RHY volatility
RHY Beta3.94
Industry Beta0.61
Market Beta1

Stable Share Price: RHY is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: RHY's weekly volatility has decreased from 15% to 10% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2017n/aGlenn Gilberthttps://www.rhythmbio.com

Rhythm Biosciences Limited, a transformative diagnostics company, engages in developing and commercializing of medical diagnostics technology in Australia and internationally. It develops ColoSTAT, a blood test for the early detection of colorectal cancer. The company was incorporated in 2017 and is headquartered in Parkville, Australia.

Rhythm Biosciences Fundamentals Summary

How do Rhythm Biosciences's earnings and revenue compare to its market cap?
RHY fundamental statistics
Market CapAU$254.74m
Earnings (TTM)-AU$6.61m
Revenue (TTM)AU$1.11m

230.2x

P/S Ratio

-38.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
RHY income statement (TTM)
RevenueAU$1.11m
Cost of RevenueAU$0
Gross ProfitAU$1.11m
ExpensesAU$7.72m
Earnings-AU$6.61m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.032
Gross Margin100.00%
Net Profit Margin-596.49%
Debt/Equity Ratio0.0%

How did RHY perform over the long term?

See historical performance and comparison

Valuation

Is Rhythm Biosciences undervalued compared to its fair value and its price relative to the market?

149.33x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate RHY's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate RHY's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: RHY is unprofitable, so we can't compare its PE Ratio to the Australian Healthcare industry average.

PE vs Market: RHY is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate RHY's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: RHY is overvalued based on its PB Ratio (149.3x) compared to the AU Healthcare industry average (2.1x).


Future Growth

How is Rhythm Biosciences forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

76.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: RHY is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).

Earnings vs Market: RHY is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: RHY's is expected to become profitable in the next 3 years.

Revenue vs Market: RHY is forecast to have no revenue next year.

High Growth Revenue: RHY is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if RHY's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Rhythm Biosciences performed over the past 5 years?

-37.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: RHY is currently unprofitable.

Growing Profit Margin: RHY is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: RHY is unprofitable, and losses have increased over the past 5 years at a rate of 37.2% per year.

Accelerating Growth: Unable to compare RHY's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: RHY is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (61.3%).


Return on Equity

High ROE: RHY has a negative Return on Equity (-387.4%), as it is currently unprofitable.


Financial Health

How is Rhythm Biosciences's financial position?


Financial Position Analysis

Short Term Liabilities: RHY's short term assets (A$2.5M) exceed its short term liabilities (A$1.3M).

Long Term Liabilities: RHY's short term assets (A$2.5M) exceed its long term liabilities (A$19.7K).


Debt to Equity History and Analysis

Debt Level: RHY is debt free.

Reducing Debt: RHY had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: RHY has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: RHY has less than a year of cash runway if free cash flow continues to reduce at historical rates of 32.9% each year


Dividend

What is Rhythm Biosciences's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate RHY's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate RHY's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if RHY's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if RHY's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of RHY's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.0yrs

Average management tenure


CEO

Glenn Gilbert

2.92yrs

Tenure

AU$551,329

Compensation

Mr. Glenn Gilbert has been Chief Executive Officer of Rhythm Biosciences Limited since November 27, 2018 and had been its Chief Operating Officer since May 21, 2018 until November 27, 2018. Mr. Gilbert ser...


CEO Compensation Analysis

Compensation vs Market: Glenn's total compensation ($USD409.21K) is about average for companies of similar size in the Australian market ($USD555.78K).

Compensation vs Earnings: Glenn's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: RHY's management team is considered experienced (3 years average tenure).


Board Members

Experienced Board: RHY's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: RHY insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.6%.


Top Shareholders

Company Information

Rhythm Biosciences Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Rhythm Biosciences Limited
  • Ticker: RHY
  • Exchange: ASX
  • Founded: 2017
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: AU$254.736m
  • Shares outstanding: 208.80m
  • Website: https://www.rhythmbio.com

Location

  • Rhythm Biosciences Limited
  • Bio21 Institute
  • 30 Flemington Road
  • Parkville
  • Victoria
  • 3010
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/16 07:04
End of Day Share Price2021/10/15 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.